David Hamilton has an article at VentureBeat about how viable the business model behind companies like 23andMe will turn out to be. He predicts that these consumer genomics companies will actually get most of their revenue from pharma, which he says are likely to pay for "access to the aggregate genetic information 23andMe amasses from its customers." GTO wonders how many of these customers understand the real details of whatever privacy policy they're given.